Evotec and Padlock Therapeutics Extend Collaboration
News Jan 09, 2015
Evotec AG and Padlock Therapeutics, Inc. have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014. Padlock is a company that is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation and immune complex formation in autoimmune diseases.
The collaboration initially began in January 2014 and now extends through March 2017. As part of the collaboration, Evotec provides a full range of research activities and expertise to Padlock including in vitro biology, high-throughput screening, structural biology, medicinal and computational chemistry and DMPK. Over the next period, Evotec and Padlock will progress multiple programmes through hit-to-lead and lead optimisation with the goal of delivering multiple development candidates. Under the terms of the initial agreement, Evotec was awarded a success payment and equity grant in addition to research payments. In the next phase of this agreement, Evotec is eligible for over $ 13 m in research payments and milestones.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are excited to continue collaborating with Padlock. This collaboration highlights how Evotec's integrated drug discovery platform provides a unique complement to Padlock's innovative approach to this target class and associated therapeutic area. We look forward to mutual success over the coming years."
Dr Michael Gilman, Chief Executive Office Padlock Therapeutics, added: "Evotec has been an innovative and supportive partner during Padlock's successful seed phase. We look forward to continuing our work with Evotec scientists toward PAD-targeted medicines as fundamentally new therapies for patients with autoimmune disease."
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.